Apellis PharmaceuticalsAPLS
About: Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Employees: 710
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
212% more call options, than puts
Call options by funds: $104M | Put options by funds: $33.5M
37% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 71
20% more capital invested
Capital invested by funds: $3.38B [Q3] → $4.04B (+$667M) [Q4]
5.73% more ownership
Funds ownership: 96.14% [Q3] → 101.87% (+5.73%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]
2% less first-time investments, than exits
New positions opened: 60 | Existing positions closed: 61
2% less funds holding
Funds holding: 261 [Q3] → 257 (-4) [Q4]
Research analyst outlook
13 Wall Street Analysts provided 1 year price targets over the past 3 months
13 analyst ratings
Mizuho Graig Suvannavejh 42% 1-year accuracy 8 / 19 met price target | 20%upside $20 | Neutral Maintained | 14 May 2025 |
Raymond James Ryan Deschner 91% 1-year accuracy 10 / 11 met price target | 211%upside $52 | Outperform Downgraded | 9 May 2025 |
B of A Securities Tazeen Ahmad 29% 1-year accuracy 9 / 31 met price target | 38%upside $23 | Neutral Downgraded | 9 May 2025 |
RBC Capital Luca Issi 20% 1-year accuracy 11 / 55 met price target | 8%upside $18 | Sector Perform Maintained | 8 May 2025 |
Scotiabank Greg Harrison 32% 1-year accuracy 13 / 41 met price target | 20%upside $20 | Sector Perform Maintained | 8 May 2025 |
Financial journalist opinion
Based on 10 articles about APLS published over the past 30 days









